Losartan-induced sprue-like enteropathy: A case report
DOI:
https://doi.org/10.22516/25007440.1532Keywords:
Losartán, angiotensin II receptor antagonists, diarrheaAbstract
Introduction: Sprue-like enteropathy induced by angiotensin II receptor antagonists (ARBs) is an uncommon entity, initially described with olmesartan and later with other drugs in the same class. It is characterized by chronic diarrhea, weight loss, and histological changes similar to celiac disease, but with negative serology.
Case presentation: We present the case of a 75-year-old woman receiving long-term treatment with losartan who developed diarrhea and progressive weight loss. Duodenal biopsies showed villous atrophy and chronic inflammation. After discontinuing the drug, the patient achieved complete clinical resolution.
Discussion: The differential diagnosis includes refractory celiac disease, inflammatory bowel disease, and infectious enteropathies. The key finding is the temporal relationship with drug use, the absence of positive serology for celiac disease, and resolution of symptoms after withdrawing the ARB.
Conclusion: This case reinforces the importance of considering ARB-induced enteropathy in the differential diagnosis of chronic diarrhea, especially in the presence of negative celiac serology.
Downloads
References
Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87(8):732–8. https://doi.org/10.1016/j.mayocp.2012.06.003
Kamal A, Fain C, Park A, Wang P, Gonzalez-Velez E, Leffler DA, et al. Angiotensin II receptor blockers and sprue-like enteropathy: a systematic review. Gastroenterol Rep (Oxf). 2019;7(3):162–7. https://doi.org/10.1093/gastro/goz019
Ianiro G, Bibbò S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40(1):16–23. https://doi.org/10.1111/apt.12780
Schiepatti A, Sanders DS, Baiardi P, Caio G, Ciacci C, Kaukinen K, et al. Nomenclature and diagnosis of seronegative coeliac disease and chronic non-coeliac enteropathies in adults: the Paris consensus. Gut. 2022;71(11):2218-25. https://doi.org/10.1136/gutjnl-2021-326645
Negro A, Blanco I. A case of severe sprue-like enteropathy associated with losartan. J Clin Gastroenterol. 2015;49(9):794–5. https://doi.org/10.1097/MCG.0000000000000383
Mazhar A, Arnautovic J. Losartan-induced sprue-like enteropathy. Am J Gastroenterol. 2017;112(Suppl):S1359. https://doi.org/10.14309/00000434-201710001-02424
Marietta EV, Nadeau AM, Cartee AK, Singh I, Rishi A, Choung RS, et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther. 2015;42(11–12):1303–14. https://doi.org/10.1111/apt.13413
U.S. Food and Drug Administration [Internet]. FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. Silver Spring: FDA; 2013 [citado el 4 de enero de 2026]. Disponible en: https://www.fda.gov/media/86382/download
Dreifuss SE, Tomizawa Y, Farber NJ, Davison JM, Sohnen AE. Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea. Case Rep Gastrointest Med. 2013;2013:618071. https://doi.org/10.1155/2013/618071
Herman ML, Rubio-Tapia A, Wu TT, Murray JA. A case of severe sprue-like enteropathy associated with valsartan. ACG Case Rep J. 2015;2(2):92–94. https://doi.org/10.14309/crj.2015.15
Menne J, Haller H. Olmesartan and intestinal adverse effects in the ROADMAP study. Mayo Clin Proc. 2012;87(12):1230-1. https://doi.org/10.1016/j.mayocp.2012.10.005
DeGaetani M, Tennyson CA, Lebwohl B, Lewis SK, Abu Daya H, Arguelles-Grande C, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108(5):647-53. https://doi.org/10.1038/ajg.2013.45
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Revista colombiana de Gastroenterología

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

| Article metrics | |
|---|---|
| Abstract views | 11 |
| Galley views | 2 |
| PDF Views | 2 |
| HTML views | 0 |
| Other views | 0 |














